Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 2, 2012
Previous Article Next Article

Inhibition of bromodomain-mediated protein–protein interactions as a novel therapeutic strategy

Author affiliations

Abstract

A multitude of epigenetic regulatory mechanisms is reflected in the dynamic nature of chromatin during different development stages as well as pathological states of human organisms. Apart from enzymatic processes, the recognition of histone modifications by reader protein modules contributes to the equilibrium between transcriptionally active and silent chromatin. Bromodomains are involved in the recognition of acetylated lysine containing substrates and in the downstream signalling of histoneacetylation. In part, this is mediated by the regulation of further acetylation reactions. Development of small molecules as epigenetic tools able to block proteinprotein interactions provided by bromodomains is a new emerging focus of epigenetic research, which also holds great potential for novel therapeutical approaches. This review is dealing with fundamentals of bromodomain structural biology, their inhibitors, and the relevance of these phenomena to molecular biology and drug discovery.

Graphical abstract: Inhibition of bromodomain-mediated protein –protein interactions as a novel therapeutic strategy

Back to tab navigation

Article information


Submitted
04 Aug 2011
Accepted
28 Sep 2011
First published
21 Oct 2011

Med. Chem. Commun., 2012,3, 123-134
Article type
Review Article

Inhibition of bromodomain-mediated proteinprotein interactions as a novel therapeutic strategy

S. D. Furdas, L. Carlino, W. Sippl and M. Jung, Med. Chem. Commun., 2012, 3, 123
DOI: 10.1039/C1MD00201E

Search articles by author

Spotlight

Advertisements